In recent years, the development of ustekinumab and vedolizumab has further improved
the treatment of inflammatory bowel disease (IBD), offering additional therapeutic
options to achieve induction and maintenance of remission in both ulcerative colitis
(UC) and Crohn's disease (CD). However, data about the impact on extra-intestinal
manifestations (EIMs) of IBD are limited [
[1]
]. In this issue, Margolin et al. [
[2]
] have reported the effect of ustekinumab and vedolizumab in EIMs of IBD.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Digestive and Liver DiseaseAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases.JGH Open: Open Access J Gastroenterol Hepatol. 2018; 2: 223-234
- Ustekinumab and vedolizumab for extraintestinal manifestations in inflammatory bowel disease - a retrospective study.Dig Liver Dis. 2023; 55: 223-229
- The impact of vedolizumab and ustekinumab on articular extra-intestinal manifestations in inflammatory bowel disease patients: a real-life multicentric cohort study.J Crohn's Colitis. 2022;
- Incidence of arthritis/arthralgia in inflammatory bowel disease with long-term vedolizumab treatment: post hoc analyses of the GEMINI trials.J Crohn's Colitis. 2019; 13: 50-57
- Vedolizumab treatment in extra-intestinal manifestations in inflammatory bowel disease: a systematic review.J Crohn's Colitis. 2019; 13: 1569-1577
- Comment on: emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease.Rheumatology. 2019; 58: 1113-1115
- Paradoxical inflammation induced by anti-TNF agents in patients with IBD.Nat Rev Gastroenterol Hepatol. 2012; 9: 496-503
- Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease.Nat Rev Immunol. 2006; 6: 244-251
- Ustekinumab for extra-intestinal manifestations of inflammatory bowel disease: a systematic literature review.J Crohn's Colitis. 2021; 15: 1236-1243
- Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab.Arch Dermatol. 2011; 147: 1203-1205
- Two cases of successful ustekinumab treatment for non-infectious uveitis associated with Crohn's disease.J Crohn's Colitis. 2020; 14: 571
- Targeting interleukin-23 in the treatment of noninfectious uveitis.Ophthalmology. 2018; 125: 1977-1983
- Ustekinumab for Crohn's disease: results of the ICC registry, a nationwide prospective observational cohort study.J Crohn's Colitis. 2020; 14: 33-45
- Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials.Ann Rheum Dis. 2014; 73: 1000-1006
- Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis.Arthritis Rheumatol. 2019; 71: 258-270
- Long-term clinical effectiveness of ustekinumab in patients with Crohn's disease who failed biologic therapies: a national cohort study.J Crohn's Colitis. 2019; 13: 1401-1409
- Ustekinumab treatment for hidradenitis suppurativa.J Dermatol. 2019; 46: 1215-1218
- Vedolizumab and extraintestinal manifestations in inflammatory bowel disease.Drugs. 2021; 81: 333-347
Article info
Publication history
Published online: October 29, 2022
Accepted:
October 13,
2022
Received:
October 1,
2022
Identification
Copyright
© 2022 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
